Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and PK of Dersimelagon (MT-7117) in Healthy Subjects
NCT03688022Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Oct 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dersimelagon in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration time curve from time zero to last quantifiable concentration and 1 more. Started Oct 2018; status: completed.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NCT03688022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03688022.